- Home
- PACB vs ALDX Comparison
PACB vs ALDX Comparison
Compare PACB & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PACB
- ALDX
- Stock Information
- Founded
- PACB 2000
- ALDX 2004
- Country
- PACB United States
- ALDX United States
- Employees
- PACB N/A
- ALDX N/A
- Industry
- PACB Biotechnology: Laboratory Analytical Instruments
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- PACB Industrials
- ALDX Health Care
- Exchange
- PACB Nasdaq
- ALDX Nasdaq
- Market Cap
- PACB 364.2M
- ALDX 304.9M
- IPO Year
- PACB 2010
- ALDX 2014
- Fundamental
- Price
- PACB $1.33
- ALDX $6.35
- Analyst Decision
- PACB Buy
- ALDX Strong Buy
- Analyst Count
- PACB 13
- ALDX 2
- Target Price
- PACB $2.79
- ALDX $10.00
- AVG Volume (30 Days)
- PACB 14.6M
- ALDX 560.3K
- Earning Date
- PACB 02-13-2025
- ALDX 05-01-2025
- Dividend Yield
- PACB N/A
- ALDX N/A
- EPS Growth
- PACB N/A
- ALDX N/A
- EPS
- PACB N/A
- ALDX N/A
- Revenue
- PACB $154,014,000.00
- ALDX N/A
- Revenue This Year
- PACB $9.91
- ALDX N/A
- Revenue Next Year
- PACB $28.57
- ALDX N/A
- P/E Ratio
- PACB N/A
- ALDX N/A
- Revenue Growth
- PACB N/A
- ALDX N/A
- 52 Week Low
- PACB $1.16
- ALDX $2.71
- 52 Week High
- PACB $4.57
- ALDX $6.92
- Technical
- Relative Strength Index (RSI)
- PACB 40.23
- ALDX 55.70
- Support Level
- PACB $1.46
- ALDX $4.78
- Resistance Level
- PACB $1.68
- ALDX $6.52
- Average True Range (ATR)
- PACB 0.16
- ALDX 0.53
- MACD
- PACB -0.02
- ALDX -0.06
- Stochastic Oscillator
- PACB 8.11
- ALDX 73.36
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.